Last reviewed · How we verify

Non-insulin antihyperglycemic drugs

Sanofi · Phase 3 active Small molecule

Non-insulin antihyperglycemic drugs is a Non-insulin antihyperglycemic agents (multiple subclasses) Small molecule drug developed by Sanofi. It is currently in Phase 3 development for Type 2 diabetes mellitus. Also known as: Non-insulin antihyperglycemic therapy.

Non-insulin antihyperglycemic drugs lower blood glucose through mechanisms other than insulin replacement, such as enhancing insulin secretion, improving insulin sensitivity, or reducing hepatic glucose production.

Non-insulin antihyperglycemic drugs lower blood glucose through mechanisms other than insulin replacement, such as enhancing insulin secretion, improving insulin sensitivity, or reducing hepatic glucose production. Used for Type 2 diabetes mellitus.

At a glance

Generic nameNon-insulin antihyperglycemic drugs
Also known asNon-insulin antihyperglycemic therapy
SponsorSanofi
Drug classNon-insulin antihyperglycemic agents (multiple subclasses)
ModalitySmall molecule
Therapeutic areaEndocrinology / Diabetes
PhasePhase 3

Mechanism of action

This is a broad drug class encompassing multiple mechanisms of action including sulfonylureas (stimulating pancreatic beta cells), biguanides like metformin (reducing hepatic glucose output and improving peripheral insulin sensitivity), DPP-4 inhibitors (prolonging GLP-1 action), SGLT2 inhibitors (promoting urinary glucose excretion), and thiazolidinediones (enhancing insulin sensitivity). Each subclass targets different pathophysiological aspects of type 2 diabetes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Non-insulin antihyperglycemic drugs

What is Non-insulin antihyperglycemic drugs?

Non-insulin antihyperglycemic drugs is a Non-insulin antihyperglycemic agents (multiple subclasses) drug developed by Sanofi, indicated for Type 2 diabetes mellitus.

How does Non-insulin antihyperglycemic drugs work?

Non-insulin antihyperglycemic drugs lower blood glucose through mechanisms other than insulin replacement, such as enhancing insulin secretion, improving insulin sensitivity, or reducing hepatic glucose production.

What is Non-insulin antihyperglycemic drugs used for?

Non-insulin antihyperglycemic drugs is indicated for Type 2 diabetes mellitus.

Who makes Non-insulin antihyperglycemic drugs?

Non-insulin antihyperglycemic drugs is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).

Is Non-insulin antihyperglycemic drugs also known as anything else?

Non-insulin antihyperglycemic drugs is also known as Non-insulin antihyperglycemic therapy.

What drug class is Non-insulin antihyperglycemic drugs in?

Non-insulin antihyperglycemic drugs belongs to the Non-insulin antihyperglycemic agents (multiple subclasses) class. See all Non-insulin antihyperglycemic agents (multiple subclasses) drugs at /class/non-insulin-antihyperglycemic-agents-multiple-subclasses.

What development phase is Non-insulin antihyperglycemic drugs in?

Non-insulin antihyperglycemic drugs is in Phase 3.

What are the side effects of Non-insulin antihyperglycemic drugs?

Common side effects of Non-insulin antihyperglycemic drugs include Hypoglycemia, Gastrointestinal disturbances, Weight changes, Lactic acidosis (metformin-associated).

Related